Sugi Predict

Sugi Predict / Compounds / SCHEMBL6847610

SCHEMBL6847610

SCHEMBL6847610

COC(=O)[C@@H]1C[C@H](OS(=O)(=O)c2ccc(C)cc2)CN1C(=O)OC(C)(C)C

nearest known ligand 0.47

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ NR1H2 P55055 1/20 0.47
▸ NR1H3 Q13133 1/20 0.47
▸ MCL1 Q07820 9/20 0.45
▸ MMP2 P08253 2/20 0.44
▸ ANPEP P15144 2/20 0.44
▸ ALDH1A1 P00352 3/20 0.43
▸ KMT2A Q03164 3/20 0.43
▸ CYP3A4 P08684 3/20 0.43
▸ CYP1A2 P05177 1/20 0.43
▸ POLB P06746 1/20 0.43
▸ CYP2C19 P33261 1/20 0.43
▸ PTPN1 P18031 1/20 0.42
▸ CYP2D6 P10635 1/20 0.41
▸ HSD11B1 P28845 1/20 0.41
▸ P2RX3 P56373 1/20 0.39
▸ MEN1 O00255 2/20 0.39
▸ BCL2 P10415 1/20 0.39
▸ BCL2L1 Q07817 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3182745 1.00 NR1H2 (0.47) NR1H2NR1H3MCL1MMP2ANPEP
SCHEMBL8166919 1.00 NR1H2 (0.47) NR1H2NR1H3MCL1MMP2ANPEP
SCHEMBL6847613 1.00 NR1H2 (0.47) NR1H2NR1H3MCL1MMP2ANPEP
SCHEMBL2819569 1.00 NR1H2 (0.47) NR1H2NR1H3MCL1MMP2ANPEP
SCHEMBL6847935 1.00 NR1H2 (0.47) NR1H2NR1H3MCL1MMP2ANPEP
SCHEMBL4320166 1.00 NR1H2 (0.47) NR1H2NR1H3MCL1MMP2ANPEP
SCHEMBL25097911 1.00 NR1H2 (0.47) NR1H2NR1H3MCL1MMP2ANPEP
SCHEMBL3187965 0.94 MCL1 (0.44) NR1H2NR1H3MCL1KMT2ACYP3A4
SCHEMBL30148070 0.94 MCL1 (0.44) NR1H2NR1H3MCL1KMT2ACYP3A4
SCHEMBL13481726 0.94 MCL1 (0.44) NR1H2NR1H3MCL1KMT2ACYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230416199-A1 INHIBITORS OF AMINO ACID TRANSPORT ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) 2023-12-28 — — US disclosed
US-11708344-B2 Flavone derivatives for the treatment and prophylaxis of hepatitis B virus disease HOFFMANN-LA ROCHE INC. (US) 2023-07-25 — — US disclosed
US-11708344-B2 Flavone derivatives for the treatment and prophylaxis of hepatitis B virus disease HOFFMANN-LA ROCHE INC. (US) 2023-07-25 — — US disclosed
US-11708344-B2 Flavone derivatives for the treatment and prophylaxis of hepatitis B virus disease HOFFMANN-LA ROCHE INC. (US) 2023-07-25 — — US disclosed
US-20230074887-A1 FLAVONE DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS DISEASE HOFFMANN-LA ROCHE INC. (US) 2023-03-09 — — US disclosed
US-20230074887-A1 FLAVONE DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS DISEASE HOFFMANN-LA ROCHE INC. (US) 2023-03-09 — — US disclosed
WO-2022087630-A1 INHIBITORS OF AMINO ACID TRANSPORT ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) 2022-04-28 — — WO disclosed
CN-112912371-A Flavone derivatives for treating and preventing hepatitis B virus diseases 豪夫迈·罗氏有限公司 2021-06-04 — — CN disclosed
WO-2017170765-A1 NOVEL NITROGEN-CONTAINING HETEROCYCLIC COMPOUND 田辺三菱製薬株式会社 2017-10-05 — — WO disclosed
US-9403805-B2 Antiviral compounds HOFFMANN-LA ROCHE INC. (US) 2016-08-02 — — US disclosed
US-6770741-B1 USEFUL IN TREATING CONDITIONS AND DISEASES OF A MAMMAL AND HUMAN IN WHICH AN EXCESS OF BRADYKININ OR RELATED KININS ARE PRODUCED OR INJECTED SUCH AS BY INSECT BITES SCIOS INC. 2004-08-03 — — US disclosed
US-6399629-B1 PYRROLIDINES AND PIPERIDINES FOR TREATING MICROBIAL INFECTIONS BY REDUCING EXPORT OF COADMINISTERED ANTIMICROBIAL AGENT OR COMPOUND SYNTHESIZED BY MICROBES FOR THEIR GROWTH; REDUCING IN VIVO AVAILABILITY MICROCIDE PHARMACEUTICALS, INC. 2002-06-04 — — US disclosed
US-6288036-B1 ANTIINFLAMMATORY, ANTIASTHMATIC, ANTIALLERGEN, AND ANALGESIC AGENTS; ARGININE-CONTAINING NONA- OR DECAPEPTIDES SCIOS INC. 2001-09-11 — — US disclosed
EP-0618810-B1 BRADYKININ ANTAGONIST PEPTIDES SCIOS NOVA INC (US) 2001-07-04 — — EP disclosed
WO-2000001714-A1 EFFLUX PUMP INHIBITORS MICROCIDE PHARMACEUTICALS, INC. (US) 2000-01-13 — — WO disclosed
EP-0618809-B1 BRADYKININ TYPE PEPTIDES SCIOS NOVA INC (US) 1998-08-19 — — EP disclosed
US-5385889-A Substitution of L-proline at the 7-position of the peptide hormone with a D-configuration hydroxyproline ether or thioether converts agonist into antagonist SCIOS NOVA INC. (US) 1995-01-31 — — US disclosed
EP-0618810-A4 BRADYKININ ANTAGONIST PEPTIDES. SCIOS NOVA INC (US) 1994-12-07 — — EP disclosed
EP-0618810-A1 BRADYKININ ANTAGONIST PEPTIDES SCIOS NOVA INC. (US) 1994-10-12 — — EP disclosed
WO-1992018156-A1 BRADYKININ ANTAGONIST PEPTIDES NOVA TECHNOLOGY LIMITED PARTNERSHIP (US) 1992-10-29 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230416199-A1 INHIBITORS OF AMINO ACID TRANSPORT SLC1A5, SLC7A1, SLC7A5 NR1H2 2000/4885NR1H3 2277/4885MCL1 2380/4885
US-11708344-B2 Flavone derivatives for the treatment and prophylaxis of hepatitis B virus disease CCNE2, CCNE1, CCNT1 NR1H2 135/4885NR1H3 121/4885MCL1 1788/4885
US-20230074887-A1 FLAVONE DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS DISEASE CCNE2, CCNE1, CCNT1 NR1H2 135/4885NR1H3 121/4885MCL1 1788/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.